FibroGen, Inc. (NASDAQ:FGEN) Files An 8-K Financial Statements and Exhibits

FibroGen, Inc. (NASDAQ:FGEN) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.

Story continues below

(d) Exhibits


FIBROGEN INC Exhibit
EX-99.1 2 d526638dex991.htm EX-99.1 EX-99.1 Exhibit 99.1          NEWS RELEASE FIBROGEN GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR PAMREVLUMAB TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER SAN FRANCISCO,…
To view the full exhibit click here

About FibroGen, Inc. (NASDAQ:FGEN)

FibroGen, Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body’s natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies.

An ad to help with our costs